Cluster Headache in United States
Overview
In the U.S., psychedelics that could help cluster headache patients (including psilocybin, DMT, and LSD) remain Schedule I controlled substances under the federal Controlled Substances Act. This classification creates significant legal barriers for cluster headache patients seeking these potentially life-changing treatments, as it prohibits any medical use and imposes strict penalties for possession. Some regional exceptions exist: Oregon, Colorado, and New Mexico have legalized supervised psilocybin services for adults and several cities have deprioritized enforcement for personal use of plant-based psychedelics. Reform efforts are gaining momentum, with multiple states considering medical access programs, ongoing FDA-approved clinical trials, and gradually easing federal research restrictions that could eventually lead to rescheduling for medical use.
FAQ
Legal Status & Framework
Regulatory Landscape
Patient-Specific Information
Advocacy Focus
Open Letter
Help us accelerate access to psychedelic therapies for cluster headache in the US by signing our open letter.
Take these three steps
Sign the global letter to demand governments and agencies take action now. Anyone anywhere can sign.
After signing the global letter, sign your country's open letter to demand better access to effective treatments for cluster headache in your country.
Become a ClusterFree ambassador by sharing this website and getting involved.
